Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

What MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?

Yan Y, Mai L, Zheng YB, Zhang SQ, Xu WX, Gao ZL, Ke WM.

World J Gastroenterol. 2012 Sep 7;18(33):4604-9. doi: 10.3748/wjg.v18.i33.4604.

2.

Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure.

Lai J, Yan Y, Mai L, Zheng YB, Gan WQ, Ke WM.

Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):154-9.

PMID:
23558069
3.

[Discussion on the meaning of MELD score in the opportunity of the entecavir treatment of HBeAg-negative acute-on-chronic liver failure].

Yan Y, Mai L, Zhu JY, Zhang Y, Ke WM.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011 Dec;25(6):466-9. Chinese.

PMID:
22734238
4.

[The relationship of HBeAg status with HBV DNA loads, MELD scores in patients with acute-on-chronic hepatitis B liver failure during terminal phases].

Lai J, Li XJ, Zhang SQ, Xu QH, Zhu JY, Ke WM.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Feb;26(1):51-3. Chinese.

PMID:
22919755
5.

[To investigate the opportunity of entecavir treatment for HBeAg-negative acute-on-chronic liver].

Mai L, Yan Y, Zhang SQ, Ke WM, Cao H.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2013 Aug;27(4):286-8. Chinese.

PMID:
24579477
7.

The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronic liver failure: a meta-analysis.

Yu S, Jianqin H, Wei W, Jianrong H, Yida Y, Jifang S, Liang Y, Zhi C, Hongyu J.

Ann Hepatol. 2013 May-Jun;12(3):364-72. Review.

8.

Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure.

Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, Wang YY, Luo JX.

World J Gastroenterol. 2014 Apr 28;20(16):4745-52. doi: 10.3748/wjg.v20.i16.4745.

9.

Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.

Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y.

Clin Exp Med. 2012 Sep;12(3):159-64. doi: 10.1007/s10238-011-0160-7. Epub 2011 Oct 15.

PMID:
22002708
10.

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.

Sun LJ, Yu JW, Zhao YH, Kang P, Li SC.

J Gastroenterol Hepatol. 2010 Mar;25(3):583-90. doi: 10.1111/j.1440-1746.2009.06089.x. Epub 2009 Nov 24.

PMID:
19968744
11.

Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score.

Li X, Gao F, Liu H, Zhang H, Liu Y, Ye X, Geng M, Sun L, Wang R, Li Y, Jiang Y, Wang X, Zhou G, Yang Z, Li A, Zeng H, Wang X.

Eur J Gastroenterol Hepatol. 2017 Jan;29(1):1-9.

PMID:
27749778
12.

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J.

Hepatology. 2009 Jan;49(1):72-9. doi: 10.1002/hep.22658.

PMID:
19065670
13.

[Dynamics of serum HBV DNA levels during the terminal phases of acute-on-chronic hepatitis B liver failure with different HBeAg status].

Lai J, Gan WQ, Xie DY, Zhang K, Ke WM, Gao ZL.

Zhonghua Gan Zang Bing Za Zhi. 2012 Jul;20(7):522-5. doi: 10.3760/cma.j.issn.1007-3418.2012.07.009. Chinese.

PMID:
23044238
14.

Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.

Chen CH, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM.

J Hepatol. 2014 Jun;60(6):1127-34. doi: 10.1016/j.jhep.2014.02.013. Epub 2014 Feb 26.

PMID:
24583247
15.

Influence of chronic HBV infection on superimposed acute hepatitis E.

Cheng SH, Mai L, Zhu FQ, Pan XF, Sun HX, Cao H, Shu X, Ke WM, Li G, Xu QH.

World J Gastroenterol. 2013 Sep 21;19(35):5904-9. doi: 10.3748/wjg.v19.i35.5904.

16.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Ono A, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitou S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Hepatol. 2012 Sep;57(3):508-14. doi: 10.1016/j.jhep.2012.04.037. Epub 2012 May 30.

PMID:
22659518
17.

Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.

Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL.

Aliment Pharmacol Ther. 2012 Jun;35(11):1326-35. doi: 10.1111/j.1365-2036.2012.05098.x. Epub 2012 Apr 16.

18.

Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.

Orito E, Fujiwara K, Kanie H, Ban T, Yamada T, Hayashi K.

World J Gastroenterol. 2012 Oct 21;18(39):5570-5. doi: 10.3748/wjg.v18.i39.5570.

19.

Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E.

Boglione L, Cardellino CS, De Nicolò A, Cariti G, Di Perri G, D'Avolio A.

J Med Virol. 2014 Nov;86(11):1845-50. doi: 10.1002/jmv.24038. Epub 2014 Aug 8.

PMID:
25131947
20.

[The impact of early rapid virological response on the outcomes of hepatitis B associated acute on chronic liver failure during antiviral treatment].

Chen L, Zheng CX, Lin MH, Gan QR, Lin RS, Gao HB, Huang JR, Pan C.

Zhonghua Gan Zang Bing Za Zhi. 2011 Oct;19(10):734-7. doi: 10.3760/cma.j.issn.1007-3418.2011.10.004. Chinese.

PMID:
22409843

Supplemental Content

Support Center